Skip to main content
Premium Trial:

Request an Annual Quote

Roche Discloses Potential $625M Price Tag for Ariosa

NEW YORK (GenomeWeb) – Roche disclosed this week that it is paying up to $625 million for non-invasive prenatal testing firm Ariosa Diagnostics.

The terms of the deal include a cash payment of $400 million and up to $225 million from a contingent consideration arrangement, Roche said in its financial report. It also disclosed that it is paying up to $121 million for informatics company Bina Technologies, which it acquired in December.

On Wednesday, Roche reported a 3 percent increase year over year in its full-year 2014 diagnostic revenues, including a 6 percent increase in its molecular diagnostics revenues. The company did not break out its next-generation sequencing sales, but said that excluding those sales, the MDx business was up 8 percent year over year in 2014. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.